Roche and Lilly’s Blood Test for Early Alzheimer’s Diagnosis Receives US FDA Approval
In a groundbreaking advancement for neurodegenerative disease diagnostics, Roche and Eli Lilly have received US Food and Drug Administration (FDA) approval for their blood-based test to detect Alzheimer’s disease, marking a major leap toward earlier,
In a groundbreaking advancement for neurodegenerative disease diagnostics, Roche and Eli Lilly have received US Food and Drug Administration (FDA) approval for their blood-based test to detect Alzheimer’s disease, marking a major leap toward earlier, simpler, and more accessible diagnosis of the condition.
The newly approved test, known as the Elecsys Amyloid Plasma Panel, uses a simple blood sample to detect specific biomarkers — particularly beta-amyloid protein levels — that are associated with the early development of Alzheimer’s disease. It offers a far less invasive and more affordable alternative to current diagnostic methods such as PET scans and lumbar punctures, which are often costly and limited to specialized medical centers.
According to both companies, the test can help physicians identify patients who are more likely to have amyloid plaques in the brain — a hallmark of Alzheimer’s — and may therefore benefit from further confirmatory testing or early treatment interventions.
Dr. Levi Garraway, Chief Medical Officer at Roche, stated, “This approval represents a significant step forward in improving access to Alzheimer’s diagnostics. Early detection is key to enabling timely care and potentially slowing disease progression through new therapeutic options.”
The collaboration between Roche and Lilly highlights a growing focus on precision diagnostics in neurology, where early and accurate identification of disease markers can drastically improve patient management. The test is expected to play a crucial role in supporting the rollout of new Alzheimer’s therapies, including those targeting amyloid buildup.
Industry experts have hailed the FDA’s approval as a milestone in dementia care, potentially transforming how Alzheimer’s is diagnosed worldwide. With an estimated 55 million people living with dementia globally, and Alzheimer’s accounting for up to 70% of these cases, the availability of a blood test could greatly improve early intervention and care planning.
The Elecsys Amyloid Plasma Panel is expected to be introduced in the US later this year, with global rollout anticipated in stages following regulatory approvals in other regions.
